Cardiac complications of antidepressants

• Authors: Anna Zdanowicz , Piotr Wierzbiński

Title variants

PL

Kardiologiczne powikłania leków przeciwdepresyjnych

• Languages of publication: EN

Abstracts

EN

Depressive disorders are an independent risk factor for coronary heart disease. They are also a risk factor for death in patients suffering from ischemic heart disease. Modern antidepressants such as selective serotonin reuptake inhibitors (SSRI) and selective noradrenaline reuptake inhibitors (SNRI) increase the safety of therapy in patients with depressive disorders, mainly through their favorable profile of adverse effects. However, they are not free from faults, and some risk of cardiac side effects exists, as confirmed by scientific reports.

PL

Zaburzenia depresyjne są niezależnym czynnikiem ryzyka rozwoju choroby niedokrwiennej serca. Są również czynnikiem ryzyka zgonu u pacjentów chorujących na chorobę niedokrwienną serca. Nowoczesne leki przeciwdepresyjne takie jak selektywne inhibitorywychwytu zwrotnego serotoniny (SSRI) oraz selektywne inhibitory wychwytu zwrotnego noradrenaliny (SNRI) zwiększyły bezpieczeństwo terapii pacjentów z zaburzeniami depresyjnymi, głównie poprzez swój korzystniejszy profil działań niepożądanych. Mimo tego nie są wolne od wad i pewne ryzyko kardiologicznych działań niepożądanych istnieje, co potwierdzają doniesienia naukowe.

Keywords

EN

QTc interval; SNRI; SSRI; heart arrhythmias; odstęp QTc; zaburzenia rytmu

Discipline

• MEDICINE: MEDICINE

• Publisher: Uniwersytet Medyczny w Lublinie
• Journal: Current Problems of Psychiatry
• Year: 2014
• Volume: 15
• Issue: 1
• Pages: 24-31

Dates

published

2014

Contributors

author

Anna Zdanowicz

author

Piotr Wierzbiński

References

• 1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May12;97(18):1837-47.
• 2. Lallukka T., Ferrie J.E., Rahkonen O., Shipley M.J., Pietiläinen O., Kivimäki M., Marmot M.G., Lahelma E.Change in economic diffi- culties and physical and mental functioning: Evidence from Brit- ish and Finnish employee cohorts. Scand J Work Environ Health. 2013 Apr 22. pii: 3366.
• 3. Cipriani A., Furukawa T.A., Salanti G., GeddesJ.R., HigginsJ.P., ChurchillR., WatanabeN., NakagawaA., OmoriI.M., McGuireH., TansellaM., BarbuiC.Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta- analysis. Lancet, 2009; 373: 746-758
• 4. Isbister G.K., BoweS.J., DawsonA., WhyteI.M. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-85.
• 5. Arizona Center for Education and Research on Therapeutics and The Critical Path Institute. [Accessed05/19/2010] QT drug lists by risk group. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
• 6. Alvarez P.A., Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects, Curr Drug Saf. 2010 Jan;5(1):97-104.
• 7. Monitorowanie elektrokardiograficzne w warunkach szpitalnych Stanowisko American Heart Association na podstawie: Practice standards for electrocardiographic monitoring in hospital set- tings An American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young, Drew B.J., CaliffR.M., FunkM., KaufmanE.S., KrucoffM.W., LaksM.M., MacfarlaneP.W., SommargrenC., SwirynS., Van HareG.F. Circulation, 2004; 110: 2721-2746, Medycyna Praktyczna 2005/05 str. 27-42
• 8. Wierzbiński P., Zboralski K., Orzechowska A., Florkowski A., Gałecki P., Niepożądane działania kardiologiczne leków przeciw- psychotycznych - doniesienia wstępne, Curr Probl Psychiatry2011; 12(1): 19-23
• 9. Karjalainen J., Viitasalo M., Manttari M., Manninen V., Relation Between QT Intervals and Heart Rates From 40 to 120 beats/min in Rest Electrocardiograms of Men and a Simple Method to Adjust QT Interval Values, J Am Coll Cardiol. 1994 Jun;23(7):1547-53.
• 10. Aytemir K., Maarouf N., Gallagher M.M., Yap Y.G., Waktare J.E., Malik M., Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms, Pacing Clin Electrophysiol. 1999 Sep;22(9):1397-401.
• 11. Waring W.S., Graham A., Gray J., Wilson A.D., Howell C., Bateman D.N.Evaluation of a QT nomogram for risk assessment after anti- depressant overdose, Br J Clin Pharmacol. 2010 Dec;70(6):881-5.
• 12. Bednar M.M., Harrigan E.P., Anziano R.J., Camm A.J., Ruskin J.N.The QT interwal. Prog Cardiovasc Dis, 2001; 43(5 Suppl 1): 1-45.
• 13. Chen S., Duan Q., Tang K., Zhao D., Xu Y., Serotonin and catechola- minergic polymorphic ventricular tachycardia: a possible therapeutic role for SSRIs? Cardiovasc J Afr. 2010 Jul-Aug;21(4):225-8.
• 14. Biernacka E.K., Lewostronne współczulne odnerwienie serca w leczeniu opornych zaburzeń rytmu serca zależnych od katecho- lamin, Post Kardiol Interw2011; 7, 1 (23): 61-64
• 15. Gawiński Ł, Przestrzenna dyspersja okresu repolaryzacji wywo- łana działaniem leków, Folia Cardiologica Excerpta2008, tom 3, nr 10, 477–502, przedruk z Antzelevitch C., Drug-induced spatial dispersion of repolarization, Cardiol J. 2008; 15(2): 100–121.
• 16. Nemeroff C.B. Overview of the safety of citalopram, Psychopharmacol Bull2003;37(1):96–121.
• 17. FDA Drug Safety Communication: Abnormal heart rhythms associat- ed with high doses of Celexa (citalopram hydrobromide). MedWatch, 2011. www.fda.gov/Drugs/DrugSafety/ ucm269086.htm.
• 18. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. MedWatch, 2011. www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
• 19. Worm K., Dragsholt C., Simonsen K., Kringsholm B., Citalopram concentrations in samples from autopsies and living persons. Int J Legal Med1998;111:188–90
• 20. Howland R.H. A critical evaluation of the cardiac toxicity of citalopram: part 1, J Psychosoc Nurs Ment Health Serv. 2011 Nov;49(11):13-6.
• 21. Tan J.Y., Levin G.M.Citalopram in the treatment of depression and other potential uses in psychiatry, Pharmacotherapy 1999;19: 675–89.
• 22. Isbister G.K., Friberg L.E., Stokes B., Buckley N.A., Lee C., Gunja N., Brown S.G., MacDonald E., Graudins A., Holdgate A., Duffull S.B.Acti- vated charcoal decreases the risk of QT prolongation after citalopram overdose, Ann Emerg Med. 2007 Nov;50(5):593-600, 600.e1-46.
• 23. Friberg L.E., Isbister G.K., Duffull S.B.Pharmacokinetic- pharmacodynamic modelling of QT interval prolongation follow- ing citalopram overdoses, Br J Clin Pharmacol. 2006 Feb;61(2):177-90.
• 24. Bond G.R.The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med39:273–286
• 25. Isbister G.K., Friberg L.E., Duffull S.B.Application of pharmacoki- netic-pharmacodynamic modelling in management of QT abnor- malities after citalopram overdose, Intensive Care Med. 2006 Jul;32(7):1060-5.
• 26. Catalano G., Catalano M.C., Epstein M.A., Tsambiras P.E.QTc interval prolongation associated with citalopram overdose: a case report and literature review, Clin Neuropharmacol. 2001 May-Jun;24(3):158-62.
• 27. Tarabar A.F., Hoffman R.S., Nelson L.Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest, J Med Toxicol. 2008 Jun;4(2):101-5
• 28. Beach S.R., Celano C.M., Noseworthy P.A., Januzzi J.L., Huffman J.C. QTc prolongation, torsades de pointes, and psychotropic medica- tions, Psychosomatics. 2013 Jan-Feb;54(1):1-13.
• 29. Wenzel-Seifert K., Wittmann M., Haen E.QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes, Dtsch Arztebl Int. 2011 Oct;108(41):687-93.
• 30. Sala M., Vicentini A., Brambilla P., Montomoli C., Jogia J.R., Caverzasi E., Bonzano A., Piccinelli M., Barale F., De Ferrari G.M. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy, Ann Gen Psy- chiatry. 2005 Jan25;4(1):1.
• 31. Deshmukh A., Ulveling K., Alla V., Abuissa H., Airey K.Prolonged QTc interval and torsades de pointes induced by citalopram, Tex Heart Inst J. 2012;39(1):68-70.
• 32. Yuksel F.V., Tuzer V., Goka E.Escitalopram intoxication, Eur Psychiatry. 2005 Jan;20(1):82.
• 33. van Gorp F., Whyte I.M., Isbister G.K., Clinical and ECG effects of escitalopram overdose, Ann Emerg Med. 2009 Sep;54(3):404-8.
• 34. van Gorp F., Duffull S., Hackett L.P., Isbister G.K. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal, Br J Clin Pharmacol. 2012 Mar;73(3):402-10.
• 35. Murdoch D., Keam S.J.Escitalopram: A review of its use in the management of major depressive disorder. Drugs2005;65:2379- 404.
• 36. Howland R.H. A question about the potential cardiac toxicity of escitalopram, J Psychosoc Nurs Ment Health Serv. 2012 Apr;50(4):17-20.
• 37. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., BraestrupC.Escitalopram versus citalopram: the surprising role of the R- enantiomer. Psychopharmacology (Berl). 2004;174:163-176.
• 38. Drewes P., Thijssen I., Mengel H.A single-dose, crossover phar- macokinetic study comparing racemic citalopram (40 mg) with the S-enantiomer of citalopram (escitalopram, 20 mg) in healthy male volunteers. Poster presented at the Annual Meeting of the New Clinical Data Evaluation Unit (NCDEU), Phoenix (AZ) USA. 2001; 29 May–1 June.
• 39. Hayes B.D., Klein-Schwartz W., Clark R.F., Muller A.A., Miloradovich J.E.Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med2010;39:44–8.
• 40. Scharko A.M., Schumacher J.ProlongedQTc interval in a 14-year- old girl with escitalopram overdose, J Child Adolesc Psychopharmacol. 2008 Jun;18(3):297-8.
• 41. Tseng P.T., Lee Y., Lin Y.E., Lin P.Y.Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review, Gen Hosp Psychiatry. 2012 Mar-Apr;34(2):210.e13-5.
• 42. Baranchuk A., Simpson C.S., Methot M., Gibson K., Strum D.Cor- rected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiaze- pines, Can J Cardiol. 2008 Jul;24(7):e38-40.
• 43. Glassman A.H., O’Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T.Jr., Krishnan K.R., van Zyl L.T., Swenson J.R., Finkel M.S., Landau C., Shapiro P.A., Pepine C.J., Mardekian J., Harrison W.M., Barton D., McIvor M.Sertraline treatment of major depres- sion in patients with acute MI or unstable angina. JAMA. 2002;288 (6):701-709.
• 44. Glassman A.H., Bigger J.T., Gaffney M., Van Zyl L.T. Heart rate variability in acute coronary syndrome patients with major de- pression: influence of sertraline and mood improvement, Arch Gen Psychiatry. 2007 Sep;64(9):1025-31.
• 45. Leftheriotis D., Flevari P., Ikonomidis I., Douzenis A., Liapis C., Paraskevaidis I., Iliodromitis E., Lykouras L., Kremastinos D.T.The role of the selective serotonin re-uptake inhibitor sertraline in nondepressive patients with chronic ischemic heart failure: a preliminary study, Pacing Clin Electrophysiol. 2010 Oct;33(10):1217-23.
• 46. Fernandez A., Bang S.E., Srivathsan K., Vieweg W.V. Cardiovascular side effects of newer antidepressants, Anadolu Kardiyol Derg. 2007 Sep;7(3):305-9,
• 47. de Boer R.A., van Dijk T.H., Holman N.D., van Melle J.P. QT interval prolongation after sertraline overdose: a case report, BMC Emerg Med. 2005 Jul19;5:5
• 48. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., Finkel M.S., Krishnan K.R., Gaffney M., Harrison W., Califf R.M., O'Connor C.M.SertralineAntiDepressant Heart Attack Randomized Trial Study Group, Platelet/endothelial biomarkers in depressed patients treated with the selective sero- tonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44
• 49. Jiang W., O’Connor C., Silva S.G., Kuchibhatla M., Cuffe M.S., Callwood D.D., Zakhary B., Henke E., AriasR.M., KrishnanR. SADHART-CHFInvestigators, Safety and efficacy of sertraline for depression in pa- tients with CHF (SADHART-CHF): a randomized, double-blind, pla- cebo-controlled trial of sertraline for major depression with con- gestive heart failure. Am Heart J2008; 156:437– 444
• 50. Hyttel J.Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol1994; 9 (Suppl 1): 19-26.
• 51. Pae C.U.,Kim J.J.,Lee C.U.,Lee S.J.,Chul-Lee C.L., Paik I.H., Provoked bradycardia after paroxetine administration, Gen Hosp Psychia- try. 2003 Mar-Apr;25(2):142-4.
• 52. Leonard C.E., Bilker W.B., Newcomb C., Kimmel S.E., Hennessy S.Antidepressants and the risk of sudden cardiac death and ven- tricular arrhythmia, Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):903-13.
• 53. Okayasu H., Ozeki Y., Fujii K., Takano Y., Saeki Y., Hori H., Horie M., Higuchi T., Kunugi H., Shimoda K.Pharmacotherapeutic determi- nants for QTc interval prolongation in Japanese patients with mood disorder, Pharmacopsychiatry. 2012 Nov;45(7):279-83.
• 54. Inamitsu T.Psychopharmacological treatment of patients compli- cated with cardiovascular disease, Nihon Rinsho. 2012 Jan;70(1):73-7.
• 55. Bérard A., Sheehy O., Damase-Michel C., Crespin S.Paroxetine use during pregnancy and perinatal outcomes including types of car- diac malformations in Quebec and France: a short communica- tion, Curr Drug Saf. 2012 Jul;7(3):207-10.
• 56. Einarson A.Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence, Can Fam Physician. 2010 Aug;56(8):767-8.
• 57. Wilting I., Smals O.M., Holwerda N.J., Meyboom R.H., de Bruin M.L., Egberts T.C. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry2006 Feb;163(2):325
• 58. Rajamani S., Eckhardt L.L., Valdivia C.R., Klemens C.A., Gillman B.M., Anderson C.L., Holzem K.M., Delisle B.P., Anson B.D., Makielski J.C., January C.T. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006 Nov;149(5):481-9
• 59. Nykamp D.L., Blackmon C.L., Schmidt P.E., Roberson A.G. QTc prolongation associated with combination therapy of levofloxa- cin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6
• 60. Dubnov G., Fogelman R., Merlob P.Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child. 2005 Sep;90(9):972-3.
• 61. Upward J.W., Edwards J.G., Goldie A., Waller D.G.Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol1998; 26: 399-402.
• 62. Fisch C.Effect of fluoxetine on the electrocardiogram, J Clin Psychiatry1985; 46: 42-4.
• 63. Borys D.J., Setzer S.C., Ling L.J., Reisdorf J.J., Day L.C., Krenzelok E.P.Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med1992; 10: 115-20.
• 64. Orlando R., De Martin S., Andrighetto L., Floreani M., Palatini P.Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure, Br J Clin Pharmacol. 2010 Mar;69(3):279-86.
• 65. Bhuiyan S., Tagashira H., Fukunaga K.Crucial interactions be- tween selective serotonin uptake inhibitors and sigma-1 receptor in heart failure, J Pharmacol Sci. 2013 Mar20;121(3):177-84.
• 66. Stirnimann G., Petitprez S., Abriel H., Schwick N.G. Brugada syndrome ECG provoked by the selective serotonin reuptake in- hibitor fluvoxamine, Europace. 2010 Feb;12(2):282-3.
• 67. Colucci V.J., Berry B.D.Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy, Ann Pharmacother. 2008 Jun;42(6):882-7
• 68. Kokan L., Dart R.C. Life threatening hypotension from venlafaxine overdose. Ann.Emerg.Med. 1996;27(6):815.
• 69. Howell C., Wilson A.D., Waring W.S.Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cas- es. Br J Clin Pharmacol2007; 64: 192–7
• 70. Letsas K., Korantzopoulos P., Pappas L., Evangelou D., Efremidis M., Kardaras F.QT interval prolongation associated with ven- lafaxine administration. Int J Cardiol2006; 109: 116–7.
• 71. Isbister G.K. Electrocardiogram changes and arrhythmias in venlafax- ine overdose, Br J Clin Pharmacol. 2009 May;67(5):572-6.
• 72. Fangio P., De Jonghe B., Appéré-De-Vecchi C., Lachérade J.C., Terville J.P., Outin H., Dagorn J.Acute heart failure associated with venlafaxine poisoning. Am J Emerg Med2007;25:210-1.
• 73. Peano C., Leikin J.B., Hanashiro P.K.Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine. Ann Emerg Med1997; 30: 704–8.
• 74. Bosse G.M., Spiller H.A., Collins A.M. A fatal case of venlafaxine overdose. J Med Toxicol2008; 4: 18–20.
• 75. Carnes C.A., Pickworth K.K., Botolato N.A., Raman S.V. Elevated defibrillation threshold with venlafaxine therapy. Pharmacother- apy 2004;24:1095-8.
• 76. Johnson E.M., Whyte E., Mulsant B.H., Pollock B.G., Weber E., Begley A.E., Reynolds C.F. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression, Am J Geriatr Psychiatry. 2006 Sep;14(9):796-802
• 77. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., Tran P.V., Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull2002; 36: 106-32.
• 78. Derby M.A., Zhang L., Chappell J.C., GonzalesC.R., CallaghanJ.T., LeibowitzM., EreshefskyL., HoelscherD., LeeseP.T., MitchellM.I.The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol2007;49:384-93.
• 79. Berkman L.F., Blumenthal J., Burg M., Carney R.M., Catellier D., Cowan M.J., Czajkowski S.M., DeBusk R., Hosking J., Jaffe A., Kauf- mann P.G., Mitchell P., Norman J., Powell L.H., Raczynski J.M., Schneiderman N.Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD), Effects of treating depression and low perceived social support on clinical events after myocar- dial infarction: the Enhancing Recovery in Coronary Heart Dis- ease Patients (ENRICHD) Randomized Trial, JAMA. 2003 Jun18;289(23):3106-16.

• Document Type: article